Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia Presented ByProf. Keith McCrae, Cleveland Clinic, OH, USA TrialPhase 2, PATH-HHT ConferenceASH 2023 7 February, 2024 14:54